Markets | | | Apple stock has become ubiquitous in the world of financial markets. It seems like everyone owns a bit of it. And while it’s difficult to find passionate Apple bears, the stock still trades at a P/E ratio (19) less than that of the S&P 500 (22). Currently, Apple and Microsoft are the only ... Read the Full Story |
|
From Our PartnersA number of attractive stocks - with significant upside - are currently being undervalued by the market. These "bargain" stocks offer the potential for significant gains to those investors who act quickly. This Special Report details the 5 top bargain stocks best positioned for short and long-term growth. | | Click Here to Download the FREE Report |
|
Stocks | | | The American Express earnings beat continued a string of positive earnings reports from the financial sector. The report also lent support to the notion that American consumers continue to spend – at least through the summer. Read the Full Story |
|
Stocks | | |
Earnings season has kicked off. Historically, bank stocks are among the first to report. J.P. Morgan Chase (NYSE:JPM), as expected, delivered stellar results. Wells Fargo (NYSE:WFC) came in with mixed results that were still in line with expectations. But Goldman Sachs (NYSE:GS) was a miss. Bank o... Read the Full Story |
|
Markets | | |
Speaking at Fortune’s “Brainstorm Finance” conference in September, Charles Schwab CEO Walt Bettinger disputed the notion that his firm would have a hard time appealing to millennials.
On the contrary, Bettinger pointed out that approximately 53% of Schwab’s new-to-firm ac... Read the Full Story |
|
Markets | | |
Calling a market top is part of an investing strategy known as market timing. Many investors claim market timing is impossible. Others routinely use different strategies to find out when a stock that has been trending upward runs up against unusually strong selling activity.
This is almost always... Read the Full Story |
|
|
The Early Bird Stock Of The Day IGM Biosciences, Inc., a clinical-stage biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer and autoimmune and inflammatory diseases. It develops Aplitabart, a Death Receptor 5 Agonist IgM antibody for the treatment of colorectal cancer; imvotamab, a CD20 x CD3 bispecific IgM antibody to treat myositis, as well as for the treatment of systemic lupus erythematosus and rheumatoid arthritis that is Phase Ib clinical trial; and IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of autoimmune diseases. IGM Biosciences, Inc. has a collaboration and license agreement with Genzyme Corporation to generate, develop, manufacture, and commercialize IgM antibodies. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California. | | View Today's Stock Pick |
|
